Clinical and economic burden of invasive pneumococcal disease and noninvasive all-cause pneumonia in hospitalized US adults: A multicenter analysis from 2015 to 2020

• DOI: 10.1016/j.ijid.2024.107023
• Publication Date: 2024-03-29T03:02:14Z
• Authors: Salini Mohanty; Nicole Cossrow; Kalvin C. Yu; Gang Ye; Meghan White; Vikas Gupta
• Keywords: Pneumococcal pneumonia

Objectives: To evaluate the clinical and economic outcomes in adults hospitalized with invasive pneumococcal disease (IPD) non-invasive all-cause pneumonia (ACP) overall by antimicrobial resistance (AMR) status.Methods: Hospitalized from BD Insights Research Database an ICD10 code for IPD, ACP or a positive Streptococcus pneumoniae culture/urine antigen test were included. Descriptive statistics multivariable analyses used to (in-hospital mortality, length of stay [LOS], cost per admission, hospital margin [costs – payments]).Results: The study included 88,182 adult patients at 90 US hospitals (October 2015-February 2020). Most (98.6%) had 40.2% <65 years old. Of 1,450 culture-positive patients, 37.7% isolate resistant ≥1 antibiotic class. Observed median LOS, margins 8.3%, 6 days, $9,791, $11, respectively. Risk factors mortality ≥50 age, higher risk (based on chronic immunocompromising conditions), intensive care unit admission. Patients IPD similar rates compared ACP, but greater costs admission LOS.Conclusion: are associated substantial burden across all age groups. Expanded vaccination programs may help reduce decrease costs.